---
title: "INKT: Directors and auditor elected, immune restoration strategy advanced, and global trials expanded"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290072379.md"
description: "The meeting approved the election of directors and auditor, confirmed a quorum, and outlined a strategy focused on immune restoration across diseases. Key initiatives include advancing clinical trials in ARDS, expanding global access, and securing external funding for new therapies.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-17T14:49:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290072379.md)
  - [en](https://longbridge.com/en/news/290072379.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290072379.md)
generator: "portal-rs"
---

# INKT: Directors and auditor elected, immune restoration strategy advanced, and global trials expanded

The meeting approved the election of directors and auditor, confirmed a quorum, and outlined a strategy focused on immune restoration across diseases. Key initiatives include advancing clinical trials in ARDS, expanding global access, and securing external funding for new therapies.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [INKT.US](https://longbridge.com/en/quote/INKT.US.md)

## Related News & Research

- [GNFT: Scalable MASH diagnostics could surpass $1.5B U.S. sales by 2033, driven by new therapies and adoption](https://longbridge.com/en/news/298480140.md)
- [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md)
- [VRTX: Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook](https://longbridge.com/en/news/298508921.md)
- [Incannex wins US patent for IHL-42X obstructive sleep apnea treatment, expiry 2040](https://longbridge.com/en/news/298450120.md)
- [Tyra Biosciences reports 79% response rate in Phase 2 bladder cancer study of dabogratinib at 60 mg dose](https://longbridge.com/en/news/298445177.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**